This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS)

Inclusion Criteria:

• Signed Informed Consent Form

• Able to comply with the study protocol, in the investigator's judgment

• Completed the treatment period of Roche sponsored ocrelizumab P-trials

Exclusion Criteria:

• Hypersensitivity to ocrelizumab or to any of its excipients.

• Participantss in a severely immunocompromised state until the condition resolves.

• Evidence of any adverse event potentially attributable to ocrelizumab, for which thelocal label recommends permanent discontinuation.

• Existence of a contra-indication as per SmPC

• Prohibited concomitant medication as specified in protocol

• Participants intending to become pregnant during the study or within 6 months afterthe last dose of the study drug in the parent study